Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

Downloads

Investor Inquiries

We are a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases.

We aspire to develop best-in-class medicines across multiple therapeutic modalities using PRISM TM, our proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, we are targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future.

Innovative Platform

Foundation of Neurology Programs

Clinical Development Expertise

GMP Manufacturing

 

Investor Relations

Recent News

Events

Recent News

Events

Recent News and Events
Change
MarketCap
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Analyst Coverage

Wave Life Sciences is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Wave Life Sciences' performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Wave Life Sciences or its management. Wave Life Sciences does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.